The Resistance Phenomenon in Microbes and Infectious Disease Vectors Implications for Human Health and Strategies for Containment: Workshop Summary (2003) / Chapter Skim
Currently Skimming:
Appendix F: Executive Summary: Interagency Task Force Report
Appendix F: Executive Summary: Interagency Task Force Report
Pages 279-286
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 279... ...
. Input from state and local health agencies, universities, professional societies, pharmaceutical companies, health care delivery organizations, agricultural producers, consumer groups, and other members of the public was important in developing the plan.
|
From page 280... ...
Develop and implement a coordinated national plan for AR surveillance; · Ensure the availability of reliable drug susceptibility data for surveillance; Monitor patterns of antimicrobial drug use; and Monitor AR in agricultural settings to protect the public's health by ensuring a safe food supply as well as animal and plant health. A coordinated national surveillance plan for monitoring AR in microorganisms that pose a threat to public health will be developed and implemented.
|
From page 281... ...
The accuracy of AR detection and reporting will be improved through training and proficiency testing programs for diagnostic laboratories and by promoting and further refining standardized methods for detecting drug resistance in important pathogens, including bacteria, parasites, fungi, and viruses. Public and private sector partners will address barriers to AR testing and reporting, e.g., barriers due to changes in health care delivery.
|
From page 282... ...
Reduced rates of infection transmission will be addressed through public health campaigns that promote vaccination and hygienic practices such as hand washing, safe food handling, and other behaviors associated with prevention of infection transmission. Infection control in health care settings will be enhanced by developing new interventions based on rapid diagnosis, improved understanding of the factors that promote crossinfection, and modified medical devices or procedures that reduce the risk of infection.
|
From page 283... ...
Basic and clinical research provides the fundamental knowledge necessary to develop appropriate responses to antimicrobial resistance emerging and spreading in hospitals, communities, farms, and the food supply. Priority Goals and Action Items in this focus area address ways to: .
|
From page 284... ...
Current and projected gaps in the arsenal of AR products and potential markets for these products will be reported to researchers and drug manufacturers through an interagency working group convened to identify and publicize priority public health needs. The development of urgently needed AR products will be stimulated throughout the process from drug discovery through licensing.
|
From page 285... ...
Surveillance . With partners, design and implement a national AR surveillance plan that defines national, regional, state, and local surveillance activities and the roles of clinical, reference, public health, and veterinary laboratories.
|
From page 286... ...
Product Development · Create an Interagency AR Product Development Working Group to identify and publicize priority public health needs in human and animal medicine for new AR products (e.g., innovative drugs, targeted spectrum antibiotics, point-of-care diagnostics, vaccines and other biologics, antiinfective medical devices, and disinfectants)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.